Naproxen ER FDA guidance [Regulatives / Guidelines]

posted by jag009  – NJ, 2014-04-15 17:36 (4456 d 10:27 ago) – Posting: # 12842
Views: 4,523

Hi Helmut and Mac,

Probably use the same approach as in assessing lagtime similarity between T and R. We did that before for a product with specific lagtime, Covera HS (for FDA). Yes nonparametric test will do (Wilcoxon signed rank test was what we submitted with and no issue came back.

John


Edit: This is your post #500. Congratulations! :flower: [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
258 visitors (0 registered, 258 guests [including 29 identified bots]).
Forum time: 04:04 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5